目的 研究分析中国药学会医药经济信息网(CMEI)网员医院近5年高血压治疗药物使用情况及变化趋势,为未来相关疾病防控、医疗保障政策的调整提供数据支撑。方法 运用描述性统计分析方法,对2013~2017年CMEI连续样本医院中5大类高血压治疗药物的品种结构、金额、用药频度进行分析与比较,并对比分析医保(2009年版)及基药(2012年版)品种使用情况。对2017年全样本医院、不同地区、不同级别使用金额及频度前10位进行排序。结果 2013~2017年连续样本医院高血压治疗药物共84个通用名、256个品规,其中属于2009年版国家医保目录的共54个通用名、203个品规;属于2012年版国家基本药物目录的共22个通用名、42个品规,不同地区、不同级别医院高血压治疗品种略有差异;5大类品种5年以来金额占比与频度占比结构略有调整,年度金额增速与频度增速逐年放缓。医保及基药使用金额及频度占比逐渐降低。2017年度不同地区、不同级别使用金额与频度排名前10位品种较为集中,基本药物品种数较少但仍占了年度使用金额的20.01%,使用频度的24.13%。结论 二、三级医院高血压治疗药物使用金额和频度的年度增速逐步放缓与分级诊疗、医药分开相关政策的推行有关。高血压治疗基本药物品种在医院高血压治疗中发挥了重要作用。应适时根据新品种的临床应用情况,科学调整基本药物及医疗保险目录。

OBJECTIVE To analyze the usage and trends of medicines for hypertension in continuous membership hospital of Chinese medicine and economic information(CMEI) network during recent 5 years and offer data and evidences for the optimization of diseases control and medical insurance policy. METHODS The medicines structure and indexes of usage amount, DDDs, annually increasing rate were analyzed and calculated. And the usage of medicines in essential medicine list and medical insurance list were compared. The top 10 of sum and DDDs in 2017 were ranked among the hospital from different regions and different levels. RESULTS During recent 5 years, 84 generic medicines and 256 products were used in CMEI membership hospital, among which 54 generic medicines and 203 products were in the national medical insurance list, 22 generic medicines and 42 products were in the national essential medical list. The sum and DDDs proportion structure of 5 different ATC sub-class appreciably changed during 5 years. The annual increase rate of total sum and DDDs slowed down gradually. The sum and DDDs proportion of medicine in national medical insurance list and national essential medical list were decreased annually. The top 10 produces of sum and DDDs in the hospital from different regions and levels in 2017 were concentrated. The essential medicines in the top 10 rank were fewer but took the 20.01% of the sum and 24.13% of the DDDs in 2017. CONCLUSION Due to the hierarchical diagnosis and separation medicines sales from hospital, the increase rate of sum and DDDs of medicines for hypertension in hospital slows down gradually. The essential medicine plays an important role in hypertension treatment. The national medical insurance list and national essential medicine list should be optimized according to the clinical advantage and evidence from the newer and innovated medicines.